193 related articles for article (PubMed ID: 37170847)
1. Margetuximab in HER2-positive metastatic breast cancer.
Gradishar WJ; O'Regan R; Rimawi MF; Nordstrom JL; Rosales MK; Rugo HS
Future Oncol; 2023 May; 19(16):1099-1112. PubMed ID: 37170847
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial.
Rugo HS; Im SA; Cardoso F; Cortés J; Curigliano G; Musolino A; Pegram MD; Wright GS; Saura C; Escrivá-de-Romaní S; De Laurentiis M; Levy C; Brown-Glaberman U; Ferrero JM; de Boer M; Kim SB; Petráková K; Yardley DA; Freedman O; Jakobsen EH; Kaufman B; Yerushalmi R; Fasching PA; Nordstrom JL; Bonvini E; Koenig S; Edlich S; Hong S; Rock EP; Gradishar WJ;
JAMA Oncol; 2021 Apr; 7(4):573-584. PubMed ID: 33480963
[TBL] [Abstract][Full Text] [Related]
3. Margetuximab for the treatment of HER2-positive metastatic breast cancer.
Tarantino P; Morganti S; Uliano J; Giugliano F; Crimini E; Curigliano G
Expert Opin Biol Ther; 2021 Feb; 21(2):127-133. PubMed ID: 33238772
[TBL] [Abstract][Full Text] [Related]
4. Margetuximab: First Approval.
Markham A
Drugs; 2021 Apr; 81(5):599-604. PubMed ID: 33761116
[TBL] [Abstract][Full Text] [Related]
5. Clinical development and current role of margetuximab for the treatment of breast cancer.
Tarantino P; Uliano J; Morganti S; Giugliano F; Crimini E; Curigliano G
Drugs Today (Barc); 2021 Sep; 57(9):551-558. PubMed ID: 34586103
[TBL] [Abstract][Full Text] [Related]
6. Role of Fcγ receptors in HER2-targeted breast cancer therapy.
Musolino A; Gradishar WJ; Rugo HS; Nordstrom JL; Rock EP; Arnaldez F; Pegram MD
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 34992090
[TBL] [Abstract][Full Text] [Related]
7. Margetuximab and trastuzumab deruxtecan: New generation of anti-HER2 immunotherapeutic agents for breast cancer.
Nur Husna SM; Wong KK
Mol Immunol; 2022 Dec; 152():45-54. PubMed ID: 36272249
[TBL] [Abstract][Full Text] [Related]
8. Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial.
Catenacci DVT; Kang YK; Park H; Uronis HE; Lee KW; Ng MCH; Enzinger PC; Park SH; Gold PJ; Lacy J; Hochster HS; Oh SC; Kim YH; Marrone KA; Kelly RJ; Juergens RA; Kim JG; Bendell JC; Alcindor T; Sym SJ; Song EK; Chee CE; Chao Y; Kim S; Lockhart AC; Knutson KL; Yen J; Franovic A; Nordstrom JL; Li D; Wigginton J; Davidson-Moncada JK; Rosales MK; Bang YJ;
Lancet Oncol; 2020 Aug; 21(8):1066-1076. PubMed ID: 32653053
[TBL] [Abstract][Full Text] [Related]
9. Significant response to margetuximab in Chinese HER2-positive metastatic breast cancer patient who progressed after second-line targeted therapy.
Li J; Lu Q; Zhou H; Xu F; Huang J; Hong R; Wang S
Anticancer Drugs; 2023 Aug; 34(7):892-895. PubMed ID: 36729856
[TBL] [Abstract][Full Text] [Related]
10. Profile of Margetuximab: Evidence to Date in the Targeted Treatment of Metastatic HER2-positive Breast Cancer.
Schlam I; Nunes R; Lynce F
Onco Targets Ther; 2022; 15():471-478. PubMed ID: 35509453
[TBL] [Abstract][Full Text] [Related]
11. First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors.
Bang YJ; Giaccone G; Im SA; Oh DY; Bauer TM; Nordstrom JL; Li H; Chichili GR; Moore PA; Hong S; Stewart SJ; Baughman JE; Lechleider RJ; Burris HA
Ann Oncol; 2017 Apr; 28(4):855-861. PubMed ID: 28119295
[TBL] [Abstract][Full Text] [Related]
12. FDA Approval Summary: Margetuximab plus Chemotherapy for Advanced or Metastatic HER2-Positive Breast Cancer.
Royce M; Osgood CL; Amatya AK; Fiero MH; Chang CJG; Ricks TK; Shetty KA; Kraft J; Qiu J; Song P; Charlab R; Yu J; King KE; Rastogi A; Janelsins B; Weinberg WC; Clouse K; Borders-Hemphill V; Brown L; Gomez-Broughton C; Li Z; Nguyen TT; Qiu Z; Ly AT; Chang S; Gao T; Tu CM; King-Kallimanis B; Pierce WF; Chiang K; Lee C; Goldberg KB; Leighton JK; Tang S; Pazdur R; Beaver JA; Amiri-Kordestani L
Clin Cancer Res; 2022 Apr; 28(8):1487-1492. PubMed ID: 34916216
[TBL] [Abstract][Full Text] [Related]
13. A Review of Margetuximab-Based Therapies in Patients with HER2-Positive Metastatic Breast Cancer.
Alasmari MM
Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612034
[TBL] [Abstract][Full Text] [Related]
14. Margetuximab with retifanlimab as first-line therapy in HER2+/PD-L1+ unresectable or metastatic gastroesophageal adenocarcinoma: MAHOGANY cohort A.
Catenacci DVT; Kang YK; Yoon HH; Shim BY; Kim ST; Oh DY; Spira AI; Ulahannan SV; Avery EJ; Boland PM; Chao J; Chung HC; Gardner F; Klempner SJ; Lee KW; Oh SC; Peguero J; Sonbol MB; Shen L; Moehler M; Sun J; Li D; Rosales MK; Park H
ESMO Open; 2022 Oct; 7(5):100563. PubMed ID: 36029651
[TBL] [Abstract][Full Text] [Related]
15. Trastuzumab Deruxtecan: A Review in Unresectable or Metastatic HER2-Positive Breast Cancer.
Nie T; Blair HA
Target Oncol; 2023 May; 18(3):463-470. PubMed ID: 37129796
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic landscape of advanced HER2-positive breast cancer in 2022.
Gupta R; Gupta S; Antonios B; Ghimire B; Jindal V; Deol J; Gaikazian S; Huben M; Anderson J; Stender M; Jaiyesimi I
Med Oncol; 2022 Oct; 39(12):258. PubMed ID: 36224475
[TBL] [Abstract][Full Text] [Related]
17. Pertuzumab for the treatment of human epidermal growth factor receptor type 2-positive metastatic breast cancer.
Chung C; Lam MS
Am J Health Syst Pharm; 2013 Sep; 70(18):1579-87. PubMed ID: 23988598
[TBL] [Abstract][Full Text] [Related]
18. Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial.
Rugo HS; Im SA; Cardoso F; Cortes J; Curigliano G; Musolino A; Pegram MD; Bachelot T; Wright GS; Saura C; Escrivá-de-Romaní S; De Laurentiis M; Schwartz GN; Pluard TJ; Ricci F; Gwin WR; Levy C; Brown-Glaberman U; Ferrero JM; de Boer M; Kim SB; Petráková K; Yardley DA; Freedman O; Jakobsen EH; Gal-Yam EN; Yerushalmi R; Fasching PA; Kaufman PA; Ashley EJ; Perez-Olle R; Hong S; Rosales MK; Gradishar WJ;
J Clin Oncol; 2023 Jan; 41(2):198-205. PubMed ID: 36332179
[No Abstract] [Full Text] [Related]
19. Complete response in patient with liver metastasis of HER2-positive breast cancer following therapy with margetuximab: a case report.
Chang H; Hu T; Hu J; Ding T; Wang Q; Cheng J
Anticancer Drugs; 2023 Aug; 34(7):883-887. PubMed ID: 36730303
[TBL] [Abstract][Full Text] [Related]
20. Trastuzumab-containing regimens for metastatic breast cancer.
Balduzzi S; Mantarro S; Guarneri V; Tagliabue L; Pistotti V; Moja L; D'Amico R
Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD006242. PubMed ID: 24919460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
